Journal Logo

Simultaneous Sessions IV: Refining biomarkers for AML outcome

S1616 MEASURABLE RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA (AML) WITH T(8;21)(Q22;Q22.1); RUNX1-RUNX1T1: RESULTS OF THE AML STUDY GROUP (AMLSG)

Rücker, F.G.1; Agrawal, M.1; Corbacioglu, A.1; Weber, D.1; Kapp-Schwoerer, S.1; Gaidzik, V.I.1; Jahn, N.1; Schroeder, T.2; Wattad, M.3; Lübbert, M.4; Koller, E.5; Kindler, T.6; Götze, K.7; Ringhoffer, M.8; Westermann, J.9; Fiedler, W.10; Horst, H.A.11; Greil, R.12; Schroers, R.13; Mayer, K.14; Heinicke, T.15; Krauter, J.16; Schlenk, R.F.1,17; Thol, F.18; Heuser, M.18; Ganser, A.18; Bullinger, L.9; Paschka, P.1; Döhner, H.1; Döhner, K.1

Author Information
doi: 10.1097/01.HS9.0000564712.52190.8e
  • Free

Abstract

Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.